Dermata Therapeutics, Inc. (DRMA)
- Previous Close
0.3410 - Open
0.3700 - Bid --
- Ask --
- Day's Range
0.3401 - 0.3900 - 52 Week Range
0.2320 - 2.8100 - Volume
118,878 - Avg. Volume
117,562 - Market Cap (intraday)
2.531M - Beta (5Y Monthly) 0.89
- PE Ratio (TTM)
-- - EPS (TTM)
-2.6700 - Earnings Date May 16, 2024 - May 20, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.50
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
www.dermatarx.comRecent News: DRMA
Performance Overview: DRMA
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DRMA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DRMA
Valuation Measures
Market Cap
2.39M
Enterprise Value
-5.05M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.38
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-67.36%
Return on Equity (ttm)
-125.96%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-7.79M
Diluted EPS (ttm)
-2.6700
Balance Sheet and Cash Flow
Total Cash (mrq)
7.44M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.64M
Research Analysis: DRMA
Company Insights: DRMA
DRMA does not have Company Insights